Bimatoprost is Used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Abbvie Inc in its drug Lumigan on Mar 16, 2001. Other drugs containing Bimatoprost are Durysta, Latisse. 11 different companies have introduced drugs containing Bimatoprost.

Bimatoprost Patents

Given below is the list of patents protecting Bimatoprost, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Durysta	US9492316	Prostamide-containing intraocular implants and methods of use thereof	Oct 31, 2034	Abbvie
Durysta	US9980974	Prostamide-containing intraocular implants and methods of use thereof	Oct 31, 2034	Abbvie
Durysta	US8629185	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	Jul 15, 2031	Abbvie
Durysta	US7799336	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr 24, 2029	Abbvie
Lumigan	US7851504	Enhanced bimatoprost ophthalmic solution	Jun 13, 2027	Abbvie
Durysta	US8206737	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr 07, 2027	Abbvie
Durysta	US10441543	Processes for making cyclic lipid implants for intraocular use	Dec 19, 2026	Abbvie
Durysta	US9149428	Processes for making cyclic lipid implants for intraocular use	Dec 19, 2026	Abbvie
Lumigan	US8278353	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8299118	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8309605	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8338479	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8524777	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8586630	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8772338	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8933120	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US8933127	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US9155716	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Lumigan	US9241918	Enhanced bimatoprost ophthalmic solution	Mar 16, 2025 (Expired)	Abbvie
Durysta	US8673341	Intraocular pressure reduction with intracameral bimatoprost implants	Feb 19, 2025 (Expired)	Abbvie
Latisse	US7351404	Method of enhancing hair growth	May 25, 2024 (Expired)	Abbvie
Latisse	US8101161	Method of enhancing hair growth	May 25, 2024 (Expired)	Abbvie
Durysta	US10398707	Hypotensive lipid-containing biodegradable intraocular implants and related implants	Apr 30, 2024 (Expired)	Abbvie
Latisse	US8038988	Method of enhancing hair growth	Aug 25, 2023 (Expired)	Abbvie
Latisse	US8263054	Method of enhancing hair growth	Aug 25, 2023 (Expired)	Abbvie
Latisse	US8632760	Method of enhancing hair growth	Jan 15, 2023 (Expired)	Abbvie
Latisse	US8758733	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan 15, 2023 (Expired)	Abbvie
Latisse	US8926953	Method of enhancing hair growth	Jan 15, 2023 (Expired)	Abbvie
Latisse	US8986715	Method of enhancing hair growth	Jan 15, 2023 (Expired)	Abbvie
Latisse	US9216183	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan 15, 2023 (Expired)	Abbvie
Latisse	US9226931	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan 15, 2023 (Expired)	Abbvie
Latisse	US7388029	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	Jan 21, 2022 (Expired)	Abbvie
Latisse	US8541466	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	Jan 31, 2021 (Expired)	Abbvie
Latisse	US8906962	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	Jan 31, 2021 (Expired)	Abbvie
Latisse	US9579270	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	Jan 31, 2021 (Expired)	Abbvie
Durysta	US7033605	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	Oct 20, 2020 (Expired)	Abbvie
Lumigan	US5688819	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Aug 19, 2014 (Expired)	Abbvie
Latisse	US8017655	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Nov 27, 2012 (Expired)	Abbvie
Lumigan	US8017655	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Nov 27, 2012 (Expired)	Abbvie
Latisse	US6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Sep 21, 2012 (Expired)	Abbvie
Lumigan	US6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Sep 21, 2012 (Expired)	Abbvie

Add above patents to watchlist

Bimatoprost's Family Patents

Full family tree

Bimatoprost Generic API Manufacturers

Several generic applications have been filed for Bimatoprost. The first generic version for Bimatoprost was by Apotex Inc and was approved on Dec 1, 2014. And the latest generic version is by Mankind Pharma Ltd and was approved on Mar 17, 2025.

Given below is the list of companies who have filed for Bimatoprost generic, along with the locations of their manufacturing plants worldwide.